- Home
- TNON vs ACXP Comparison
TNON vs ACXP Comparison
Compare TNON & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- ACXP
- Stock Information
- Founded
- TNON 2012
- ACXP 2017
- Country
- TNON United States
- ACXP United States
- Employees
- TNON N/A
- ACXP N/A
- Industry
- TNON Medical Specialities
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- ACXP Health Care
- Exchange
- TNON Nasdaq
- ACXP Nasdaq
- Market Cap
- TNON 10.6M
- ACXP 9.1M
- IPO Year
- TNON 2022
- ACXP 2021
- Fundamental
- Price
- TNON $1.38
- ACXP $4.48
- Analyst Decision
- TNON Strong Buy
- ACXP Strong Buy
- Analyst Count
- TNON 3
- ACXP 2
- Target Price
- TNON $11.67
- ACXP $200.00
- AVG Volume (30 Days)
- TNON 13.4M
- ACXP 53.1K
- Earning Date
- TNON 08-13-2025
- ACXP 08-12-2025
- Dividend Yield
- TNON N/A
- ACXP N/A
- EPS Growth
- TNON N/A
- ACXP N/A
- EPS
- TNON N/A
- ACXP N/A
- Revenue
- TNON $3,284,000.00
- ACXP N/A
- Revenue This Year
- TNON $39.03
- ACXP N/A
- Revenue Next Year
- TNON $66.24
- ACXP N/A
- P/E Ratio
- TNON N/A
- ACXP N/A
- Revenue Growth
- TNON 2.18
- ACXP N/A
- 52 Week Low
- TNON $0.85
- ACXP $4.17
- 52 Week High
- TNON $15.79
- ACXP $47.80
- Technical
- Relative Strength Index (RSI)
- TNON 65.80
- ACXP 26.76
- Support Level
- TNON $1.30
- ACXP $4.17
- Resistance Level
- TNON $1.63
- ACXP $9.96
- Average True Range (ATR)
- TNON 0.19
- ACXP 0.83
- MACD
- TNON 0.03
- ACXP -0.34
- Stochastic Oscillator
- TNON 27.15
- ACXP 5.35
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.